Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.51 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.43 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.43 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.43 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.43 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL796010 | 0.80 | RAB9A (0.47) | TNKS2PARP2LMNATP53RAB9A | |
| SCHEMBL20876092 | 0.80 | TNKS2 (0.50) | TNKS2PARP2LMNATP53RAB9A | |
| SCHEMBL20893213 | 0.80 | TNKS2 (0.50) | TNKS2PARP2LMNATP53RAB9A | |
| SCHEMBL18747055 | 0.80 | PARP10 (0.61) | TNKS2PARP2LMNATP53RAB9A | |
| SCHEMBL10462549 | 0.80 | CYP2C9 (0.50) | TNKS2PARP2LMNATP53RAB9A | |
| SCHEMBL4548307 | 0.80 | TNKS2 (0.46) | TNKS2PARP2LMNATP53RAB9A | |
| SCHEMBL13650900 | 0.79 | LMNA (0.55) | LMNATP53RAB9ASMN1; SMN2MAPT | |
| SCHEMBL17454456 | 0.78 | FLT3 (0.47) | TNKS2PARP2LMNATP53RAB9A | |
| SCHEMBL84416 | 0.77 | RAB9A (0.64) | TNKS2PARP2LMNATP53RAB9A | |
| SCHEMBL11353883 | 0.77 | MAPT (0.38) | TNKS2PARP2LMNATP53RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160194299-A1 | COMPOUNDS FOR TREATMENT OF DRUG RESISTANT AND PERSISTENT TUBERCULOSIS | THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH | 2016-07-07 | — | — | US | disclosed |
| WO-2014190199-A1 | COMPOUNDS FOR TREATMENT OF DRUG RESISTANT AND PERSISTENT TUBERCULOSIS | THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2014-11-27 | — | — | WO | disclosed |
| US-8168649-B2 | Niacin receptor agonists, compositions containing such compounds and methods of treatment | Merk Sharp & Dohme Corp. (US) | 2012-05-01 | — | — | US | disclosed |
| US-20100144778-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME LLC | 2010-06-10 | — | — | US | disclosed |
| US-20070299101-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. | 2007-12-27 | — | — | US | disclosed |
| US-20070299101-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. | 2007-12-27 | — | — | US | disclosed |
| US-20070179297-A1 | Chemical compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2007-08-02 | — | — | US | disclosed |
| US-20070179297-A1 | Chemical compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2007-08-02 | — | — | US | disclosed |
| US-7238811-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2007-07-03 | — | — | US | disclosed |
| US-7238811-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2007-07-03 | — | — | US | disclosed |
| US-7179922-B2 | 4-Phenyloxypiperidionopiperidine compounds as antiinflammatory agents; autoimmune diseases; rheumatic diseases; cardiovascular disorders | ASTRAZENECA AB (SE) | 2007-02-20 | — | — | US | disclosed |
| US-7179922-B2 | 4-Phenyloxypiperidionopiperidine compounds as antiinflammatory agents; autoimmune diseases; rheumatic diseases; cardiovascular disorders | ASTRAZENECA AB (SE) | 2007-02-20 | — | — | US | disclosed |
| WO-2007002557-A1 | NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| US-5919799-A | OVERCOMING RESISTANCE TO AN ANTI-NEOPLASTIC AGENT OR AN ENHANCER FOR THE EFFECT OF AN ANTI-NEOPLASTIC AGENT COMPRISING SAID ENHANCER FOR THE EFFECT OF AN ANTI-NEOPLASTIC AGENT | NIKKEN CHEMICALS CO., LTD. (JP) | 1999-07-06 | — | — | US | disclosed |
| EP-0816366-A1 | IMIDAZOTHIAZOLE COMPOUNDS | Nikken Chemicals Company, Limited (JP) | 1998-01-07 | — | — | EP | disclosed |
| US-4968708-A | Imidazo[2,1-B]benzothiazole compounds and antiulcer compositions containing the same | NIKKEN CHEMICALS CO., LTD. (JP) | 1990-11-06 | — | — | US | disclosed |
| EP-0347880-A2 | Imidazo[2,1-b]benzothiazole compounds and antiulcer compositions containing the same | NIKKEN CHEMICALS CO., LTD. (JP) | 1989-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144778-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | HCAR1, HCAR2, GPR119 | TNKS2 3369/4885PARP2 3475/4885LMNA 851/4885 |
| US-20160194299-A1 | COMPOUNDS FOR TREATMENT OF DRUG RESISTANT AND PERSISTENT TUBERCULOSIS | FNTB, PGLS, EP300 | TNKS2 2617/4885PARP2 3101/4885LMNA 2060/4885 |
| US-20070299101-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | LDLR, APOB, FFAR1 | TNKS2 3716/4885PARP2 4519/4885LMNA 732/4885 |
| US-20070179297-A1 | Chemical compounds | CCR3, CCR1, CCR4 | TNKS2 3986/4885PARP2 2969/4885LMNA 3860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.